Search clinical trials for: VNRX-7145

Total 217 results

Venatorx Pharmaceuticals, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

VNRX-7145 SAD/MAD Safety and PK in Healthy Adult Volunteers

Healthy Volunteers

United States
Venatorx Pharmaceuticals, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

VNRX-7145 Drug-Drug Interaction in Healthy Adult Volunteers

Healthy Subjects

Netherlands
Venatorx Pharmaceuticals, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Food Effect on Ceftibuten/VNRX-7145 in Healthy Participants

Pharmacokinetics

United States
Venatorx Pharmaceuticals, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Ceftibuten/VNRX-7145 in Participants With Varying Degrees of Renal Function

Pharmacokinetics

United States
Venatorx Pharmaceuticals, Inc.
National Institutes of Health (NIH)

Completed

VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment

Pharmacokinetics

United States
Venatorx Pharmaceuticals, Inc.
Novotech (Australia) Pty Limited

Terminated

VNRX-9945 Safety and Pharmacokinetics in Healthy Adult Volunteers

Healthy Volunteers

New Zealand
Venatorx Pharmaceuticals, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

VNRX-5024 Safety and PK in Healthy Adult Volunteers

Healthy Subjects

Netherlands
SecuraBio

Completed

A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)

Hematologic Malignancy

United States, Italy
Venatorx Pharmaceuticals, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers

Bacterial Infections

United States
Venatorx Pharmaceuticals, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

VNRX-5133 Drug-Drug Interaction in Healthy Adult Volunteers

Bacterial Infections

United States
Merck Sharp & Dohme LLC

Withdrawn

The Pharmacokinetics of MK-7145 Following Single Dose Administration in Participants With Moderate Renal Insufficiency (MK-7145-018)

Renal Insufficiency
Venatorx Pharmaceuticals, Inc.
National Institutes of Health (NIH)

Completed

Safety and Pharmacokinetics of VNRX-5133 in the Epithelial Lining Fluid of Healthy Adult Subjects

Healthy Subjects

United States
Naurex, Inc, an affiliate of Allergan plc

Completed

Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Naurex, Inc, an affiliate of Allergan plc

Completed

Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers (NRX-1074)

Major Depressive Disorder

United States
University of Southern California

Terminated

Oral NRX 194204 in Patients With Refractory Malignancies

Refractory Malignancies

United States
Venatorx Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections (CERTAIN-1)

Urinary Tract Infections | Acute Pyelonephritis

United States, Argentina, Brazil, Bulgaria, China, Croatia, Hungary, Latvia, Mexico, Peru, Romania, Russian Federation, Serbia, Turkey, Ukraine
Viome

Completed

Efficacy of VRx MyBiotics Oral Lozenges

Oral Microbiome Health

United States
Vestre VikenHF Kongsberg Sykehus
Norwegian Medical Association

Completed

Efficacy Side-effect Score (ESS): Development and Evaluation of a New Tool for Patients After Surgery (ESScore)

Postoperative Complications | Postoperative Pain | Postoperative Vomiting and Nausea | Mental Status Changes Postoperative

Kazakhstan, Russian Federation
SecuraBio

Completed

Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145

Healthy

United States
Molecular Insight Pharmaceuticals, Inc.

Terminated

Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma

Metastatic Melanoma

United States
Merck Sharp & Dohme LLC

Completed

A Study of MK-7145 Compared to Placebo and Hydrochlorothiazide for Lowering Blood Pressure in Male Participants With Hypertension (MK-7145-009)

Hypertension
University of Alabama at Birmingham

Recruiting

The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy

Parkinson Disease

United States
Io Therapeutics

Completed

Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer

Castration Resistant Prostate Cancer

United States
University Hospital, Tours

Withdrawn

Microglial Activation Role In ALS (MARIA) (MARIA)

Amyotrophic Lateral Sclerosis

France
NeuroRx, Inc.
Prevail Infoworks

Available

NRX-101 Expanded Access (NRX-101EAP)

Bipolar Depression | Bipolar Affective Disorder
SecuraBio

Completed

Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects (IPI-145-14)

Hepatic Impairment

United States
SecuraBio

Completed

A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects

Asthma

Germany, United Kingdom
SecuraBio

Terminated

Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL (REAL)

Lymphoma | Lymphoma, Non-Hodgkin | Follicular Lymphoma | Chronic Lymphocytic Leukemia | Lymphoma, Small Lymphocytic

United States
Amgen

Completed

Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease

Type II Refractory Celiac Disease (RCD-II) | In-situ Small Bowel T-cell Lymphoma

Spain, United States, Finland, France, Netherlands
GE Healthcare
Medpace, Inc.; Biomedical Systems; i3 Statprobe; Rules-Based Medicine, Inc.

Completed

Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure

Diabete Mellitus | Congestive Heart Failure | Chronic Renal Insufficiency

United States
Ensoma

Completed

Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment

Healthy | Renal Insufficiency

United States
Amgen

Available

AMG 714 Expanded Access Program

Celiac Disease
SecuraBio

Completed

IPI-145 ADME and Absolute Bioavailability Study

Healthy

Netherlands
EIP Pharma Inc

Completed

A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease

Netherlands
EIP Pharma Inc

Completed

Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD

Alzheimer's Disease

United States
University of Alabama at Birmingham

Recruiting

Neuroinflammation in Asymptomatic Carotid Artery Disease - Imaging Substudy

Critical Asymptomatic Carotid Artery Disease | Non-Critical Asymptomatic Carotid Artery Disease

United States
SecuraBio

Terminated

A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies

Hematologic Malignancies

United States
Pinta Biotherapeutics

Completed

Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting

End Stage Renal Disease | Kidney Disease | Protein Energy Wasting

United States
Iovance Biotherapeutics, Inc.

Completed

Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck

Squamous Cell Carcinoma of the Head and Neck

United States
Hospices Civils de Lyon

Not yet recruiting

Plaque and Brain Inflammation in Symptomatic Carotid Stenosis: Role of the Ficolin-2 (STATEMENT)

CAROTID STENOSIS

France
NYU Langone Health
Naurex, Inc, an affiliate of Allergan plc

Withdrawn

NRX-1074 in Early Course Schizophrenia

Schizophrenia

United States
Jiangsu Atom Bioscience and Pharmaceutical Co.,...

Recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers (ABP-745)

Gout

United States
Center Eugene Marquis

Withdrawn

Contribution of [18F]DPA-714 PET for Grading and Exploration of the Inflammatory Microenvironment of Glioma. (INFLAGLI)

Glioma
University of Alabama at Birmingham

Recruiting

Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714. (DPA-714)

Multiple Sclerosis | Healthy | Fibromyalgia | Chronic Fatigue Syndrome

United States
SecuraBio

Completed

A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)

Indolent Non-Hodgkin Lymphoma

Belgium, France, Italy, Spain, Canada, United States, Bulgaria, United Kingdom, Hungary, Georgia, Belarus, Czechia
EIP Pharma Inc
Amsterdam UMC, location VUmc; Worldwide Clinical Trials

Completed

Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease (REVERSE-SD)

Alzheimer Disease

United States, Netherlands, United Kingdom, Czechia, Denmark
University of Alabama at Birmingham

Recruiting

Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Infection

SARS CoV-2 Post-Acute Sequelae

United States
Ruijin Hospital

Recruiting

Neuroinflammatory PET Imaging in Autoimmune Encephalomyelitis

Autoimmune Encephalomyelitis

China
University Hospital, Toulouse
Fondation Plan Alzheimer

Completed

Effect of Neflamapimod on Brain Inflammation in Alzheimer's Disease Patients (VIP)

Alzheimer Disease

France
EIP Pharma Inc
Voisin Consulting, Inc.

Terminated

Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease

Huntington Disease

United Kingdom

Search clinical trials for: VNRX-7145

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations